FORM 6 - K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
The Securities Exchange Act of 1934
For the month of April 2000
Commission File Number 0-29350
VASOGEN INC.
(Translation of Registrant's name into English)
2155 Dunwin Drive, Suite 10, Mississauga, Ontario, L5L 4M1
(Address of principal executive offices)
(Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20 - F or Form 40 - F.)
Form 20 - F [ X ] Form 40 - F [ ]
(Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.)
Yes [ ] No [ X ]
This Form 6-K consists of:
A press release issued by Vasogen Inc. on April 19, 2000 entitled: "Vasogen
Appoints Cancer Specialist to Scientific Advisory Board"
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
VASOGEN INC.
By /S/Christopher Waddick
----------------------
(Name: Christopher Waddick)
(Title: Vice-President, Finance & CFO)
Date: April 19, 2000
<PAGE>
Vasogen Inc.
INVESTOR CONTACT
2155 Dunwin Drive, Suite 10
Mississauga, ON, Canada L5L 4M1 Trevor Burns
tel: (905) 569-2265 fax: (905) 569-9231 Investor Relations
http://www.vasogen.com tel: (905) 569-9065
e-mail: [email protected]
- --------------------------------------------------------------------------------
FOR IMMEDIATE RELEASE
VASOGEN APPOINTS CANCER SPECIALIST TO
SCIENTIFIC ADVISORY BOARD
Toronto, Ontario (April 19, 2000) - Vasogen Inc. (TSE:VAS; AMEX:MEW) is pleased
to announce the appointment of Dr. Richard G. Margolese to its Scientific
Advisory Board. Dr. Margolese is the Hebert Black Professor of Surgical Oncology
at McGill University and the Director of the Department of Oncology at Sir
Mortimer B. Davis-Jewish General Hospital in Montreal.
Dr. Margolese is internationally recognized for his leadership in both cancer
research and treatment. He is the author of numerous important scientific
publications and has served on the review and editorial boards of most major
oncology journals.
Dr. Margolese has served as Chairman of the Treatment Committee of the Breast
Cancer Task Force at the National Cancer Institute (U.S.A.) and he is the
Chairman of the Surgical Committee at the National Surgical Adjuvant Breast
Project, a position he has held for the past 20 years. He has served as
President of the National Cancer Institute of Canada, as Chairman of Cancer
2000, a Federal and Provincial Task Force on Cancer Control, and as Chairman of
the Management Committee of the Canadian Breast Cancer Research Initiative. Dr.
Margolese is the recipient of numerous awards including the Order of Canada,
and, most recently, the R.M. Taylor medal of the Canadian Cancer Society for the
year 2000.
"As we extend our development program to investigate the role of Vasogen's
cell-processing technology in the management of certain cancers, the addition of
such a prominent and accomplished individual to our Scientific Advisory Board is
an important step forward," said Dr. Eldon Smith, Vasogen's Vice President,
Scientific Affairs. "Dr. Margolese's experience and expertise in the design and
execution of clinical trials will be very helpful as we continue to advance our
product candidates through clinical development in Canada, the United States,
and the U.K."
Vasogen is focused on developing immune modulation therapies to advance the
treatment of cardiovascular, autoimmune and related inflammatory diseases.
These therapies are designed to target fundamental disease-causing events,
providing safe, effective treatment.
Statements contained in this press release, including those pertaining to
scientific and clinical research, commercialization plans, strategic alliances,
and intellectual property protection, other than statements of historical fact,
are forward-looking statements subject to a number of uncertainties that could
cause actual results to differ materially from statements made.
